MedTrace Logo

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

NCT07291635 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 728

Last updated 2026-03-13

No results posted yet for this study

Summary

This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.

Conditions

Interventions

BIOLOGICAL

Recombinant Influenza vaccine candidate

Plant-Based Seasonal Recombinant Trivalent TVLP Influenza Vaccine

BIOLOGICAL

Commercial Influenza vaccine

Influenza vaccine commercially available on the Canadian market

Sponsors & Collaborators

  • Aramis Biotechnologies Inc.

    lead INDUSTRY

Principal Investigators

  • Brian Ward, MD · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291635 on ClinicalTrials.gov